StreetInsider.com News Articles

Kamada signs $50M plasma supply deal, sales to begin in Q4 2026

Mon, 20 Jul 2026 07:01:19 -0400

Kamada Ltd. (NASDAQ: KMDA) announced a three-year agreement to supply normal source plasma to an undisclosed biopharmaceutical company focused on plasma-derived therapies. The deal is expected to generate approximately $50 million in revenue over the contract period.

Plasma supplied under the agreement will come from Kamada's collection centers in Houston and San Antonio, Texas, both of which are FDA-approved. The company said initial commercial sales under the agreement are expected to be recorded in the fourth quarter of 2026.

Each collection center has a planned capacity of approximately 50,000 liters per year at full capacity.

Amir London, Chief Executive Officer of Kamada, said

Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies

Mon, 20 Jul 2026 07:00:00 -0400

REHOVOT, Israel and HOBOKEN, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced an agreement to supply plasma to a leading biopharmaceutical company focused on plasma-derived therapies. The new three-year agreement for the supply of normal source plasma from Kamada’s plasma collection centers in Texas is expected to generate approximately $50 million in revenue over three years. Initial commercial sales under the agreement are expected to be

Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies

Mon, 20 Jul 2026 07:00:00 -0400

Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies

Mon, 20 Jul 2026 07:00:00 -0400

Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies

Mon, 20 Jul 2026 07:00:00 -0400

Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies

Mon, 20 Jul 2026 07:00:00 -0400

Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies

Mon, 20 Jul 2026 07:00:00 -0400

Form 6-K KAMADA LTD For: Jul 20

Mon, 20 Jul 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260720/26786843.html

Form 6-K KAMADA LTD For: Jul 20

Mon, 20 Jul 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260720/26786843.html

Form 6-K KAMADA LTD For: Jul 20

Mon, 20 Jul 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260720/26786843.html

Form 6-K KAMADA LTD For: Jul 13

Mon, 13 Jul 2026 07:46:00 -0400

si-local-file:///var/storage/secattach/20260713/26759906.html

Form 6-K KAMADA LTD For: Jul 13

Mon, 13 Jul 2026 07:46:00 -0400

si-local-file:///var/storage/secattach/20260713/26759906.html

Form 6-K KAMADA LTD For: Jul 13

Mon, 13 Jul 2026 07:46:00 -0400

si-local-file:///var/storage/secattach/20260713/26759906.html

Kamada shares CYTOGAM study data from 2026 ISHLT meeting

Mon, 13 Jul 2026 07:02:48 -0400

Kamada Ltd. (NASDAQ: KMDA) highlighted results from an investigator-initiated study of its CYTOGAM® product presented at the 2026 International Society for Heart and Lung Transplant annual meeting in Toronto, Canada.

The study results were presented by Dr. Daniel Calabrese, associate professor of medicine at the UCSF Lung Transplant Program, across three poster presentations. The research is part of a post-marketing program for CYTOGAM, the company's Cytomegalovirus Immune Globulin (CMVIG).

In a retrospective analysis, researchers found that CMV high-risk lung transplant recipients who did not receive CMVIG prophylaxis had worse clinical outcomes compared with those who did. A paired analysis of patient blood

Kamada shares CYTOGAM study data from 2026 ISHLT meeting

Mon, 13 Jul 2026 07:02:48 -0400

Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting